Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs

被引：6

作者：

Tawaratsumida H. ^{[1
]}

Setoguchi T. ^{[2
]}

Arishima Y. ^{[1
]}

Ohtsubo H. ^{[3
]}

Akimoto M. ^{[4
]}

Ishidou Y. ^{[5
]}

Nagano S. ^{[1
]}

Taketomi E. ^{[1
,6
]}

Sunahara N. ^{[1
,6
]}

Komiya S. ^{[1
]}

机构：

[1] Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[2] Near-Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima

[3] Center for Rheumatic Diseases, Japanese Red Cross Kagoshima Hospital, Kagoshima

[4] Department of Hematology and Immunology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[5] Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[6] Department of Orthopaedic Surgery, Japanese Red Cross Kagoshima Hospital, Kagoshima

来源：

BMC Research Notes | / 10卷 / 1期

关键词：

Biological disease-modifying anti-rheumatic drugs (bDMARDs); Osteoporosis; Rheumatoid arthritis (RA); Risk factors;

D O I：

10.1186/s13104-017-3086-7

中图分类号：

学科分类号：

摘要：

Objective: Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients' variables to identify risk factors for least significant reduction of bone mineral density. Results: Least significant reduction of lumbar spine bone mineral density (≤ - 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ - 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss. © 2017 The Author(s).

引用

共 35 条

[31] Mori Y., Kuwahara Y., Chiba S., Kogre A., Baba K., Kamimura M., Itoi E., Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment, J Bone Miner Metab., 35, 1, pp. 52-57, (2017)
[32] Kleyer A., Schett G., Arthritis and bone loss: A hen and egg story, Curr Opin Rheumatol, 26, 1, pp. 80-84, (2014)
[33] Jensen T.W., Hansen M.S., Horslev-Petersen K., Hyldstrup L., Abrahamsen B., Langdahl B., Zerahn B., Podenphant J., Stengaard-Petersen K., Junker P., Et al., Periarticular and generalised bone loss in patients with early rheumatoid arthritis: Influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial, Ann Rheum Dis, 73, 6, pp. 1123-1129, (2014)
[34] Krieckaert C.L., Nurmohamed M.T., Wolbink G., Lems W.F., Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: A cohort study, Rheumatology, 52, 3, pp. 547-553, (2013)
[35] Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., Miossec P., A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab, Arthritis Res Ther, 9, 3, (2007)

← 1 2 3 4 →